Caplin FDA Friday, February 27, 2026 0.00 Neutral

FDA Approves DESMOPRESSIN ACETATE — Caplin Steriles Limited

# FDA Approves Caplin Steriles' Intravenous Desmopressin Acetate Caplin Steriles Limited has received FDA approval for its generic intravenous desmopressin acetate formulation (ANDA219981), expanding treatment options for diabetes insipidus and hemophilia patients while potentially reducing costs in the hospital and acute care settings. The approval positions Caplin to compete in the established intravenous desmopressin market, where it may capture price-sensitive hospital formulary share from branded alternatives.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

GET FREE KEY — 10,000 calls/day